Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics (Q39334142)

11 September 2017

Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics (English)

1 reference

11 September 2017

1 reference

1 reference

Siew Hua Gan

1

1 reference

11 September 2017

Rusli Ismail

series ordinal

2

1 reference

11 September 2017

Wan Aasim Wan Adnan

series ordinal

3

1 reference

11 September 2017

Wan Zulmi

series ordinal

4

1 reference

11 September 2017

1 January 2007

1 reference

Molecular Diagnosis and Therapy

11 September 2017

1 reference

11 September 2017

11

1 reference

11 September 2017

171-181

1 reference

11 September 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03256239

11 September 2017

0 references

cites work

Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states

1 reference

https://api.crossref.org/works/10.1007%2FBF03256239

Influence of pharmacogenetics on drug disposition and response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256239

Molecular mechanisms of genetic polymorphisms of drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256239

Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256239

Pharmacogenetics in the practice of laboratory medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256239

What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256239

Multiple intramuscular injections: a major source of variability in analgesic response to meperidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256239

Achieving target goals most precisely using nonparametric compartmental models and "multiple model" design of dosage regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256239

Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256239

Population pharmacokinetic modelling of tramadol with application of the NPEM algorithms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256239

A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256239

Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256239

Review of pain-measurement tools

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256239

Population pharmacokinetics. Theory and clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256239

A population pharmacokinetic model of trimethoprim in patients with pneumocystis pneumonia, made with parametric and nonparametric methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256239

Molecular genetics of the debrisoquin-sparteine polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256239

CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256239

Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256239

Validation of a high-performance liquid chromatography method for tramadol and o-desmethyltramadol in human plasma using solid-phase extraction

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FBF03256239

21 January 2018

12 December 2020

Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study

1 reference

12 December 2020

Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic

1 reference

12 December 2020

New clinical experience with tramadol.

1 reference

12 December 2020

Tramadol: a new centrally acting analgesic

1 reference

12 December 2020

Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles

1 reference

12 December 2020

Postoperative patient-controlled analgesia with tramadol: analgesic efficacy and minimum effective concentrations.

1 reference

12 December 2020

Bioavailability of tramadol after i.m. injection in comparison to i.v. infusion

1 reference

12 December 2020

Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology

1 reference

12 December 2020

Respiratory and analgesic effects of meperidine and tramadol in patients undergoing orthopedic surgery

1 reference

12 December 2020

Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.

1 reference

12 December 2020

Failure of pain relief after surgery. Attitudes of ward staff and patients to postoperative analgesia

1 reference

12 December 2020

Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype

1 reference

12 December 2020

The effect of 'detailing' on physicians' prescribing behavior for postsurgical narcotic analgesia

1 reference

12 December 2020

A genetic bias in clinical trials? Cytochrome P450-2D6 (CYP2D6) genotype in general vs selected healthy subject populations

1 reference

12 December 2020

Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers

1 reference

12 December 2020

Tramadol hydrochloride: an overview of current use.

1 reference

12 December 2020

Clinical implications of genetic polymorphism in drug metabolism

1 reference

12 December 2020

Acute pain management: operative or medical procedures and trauma.

1 reference

12 December 2020

Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype

1 reference

12 December 2020

CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles.

1 reference

12 December 2020

1 reference

12 December 2020

The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry

1 reference

12 December 2020

Tramadol for the management of acute pain.

1 reference

12 December 2020

1 reference

12 December 2020

Heterogeneity of the CYP2D6 gene among Malays in Malaysia

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03256239

1 reference

11 September 2017

1 reference